Superworth

ADC Therapeutics SA ADCT

Drug Manufacturers - General, Healthcare
$1.54
+0.65%
Market cap
$196.6M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
2.5×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$79.6M
+3% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−52.0%

ADC Therapeutics SA trades at 2.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $79.6M over the last twelve months, up 3% on a year earlier.

Charts

Financials

Income statement for ADCT, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$14.5M$16.8M$18.1M−5%$17.4M−10%$18.5M+27%$16.9M+1%$23M+28%$18.8M+8%$16.4M−11%$23.1M+36%$20.9M−10%$19.2M+2%
Cost of revenue$208K$1.2M$2.5M$1.2M+8%$851K+309%$1.4M+13%$2.1M−18%$836K−31%$1.2M+41%$1.7M+24%$3.6M+75%$2.3M+181%
Gross profit$14.3M$15.6M$15.5M−18%$16.2M−11%$17.6M+23%$15.5M−0%$21M+35%$18M+11%$15.2M−14%$21.4M+38%$17.2M−18%$16.9M−6%
R&D$27.1M$30.3M$25.7M−33%$24.3M−23%$32.5M+20%$27.1M−11%$28.9M+12%$30.1M+24%$26.8M−18%$18.2M−33%$19.9M−31%$17.4M−42%
SG&A$23.4M$25.2M$23.4M−24%$20.9M−21%$20.7M−12%$20.9M−17%$20.5M−12%$19M−9%$19M−8%$21.4M+3%$22.6M+10%$22.3M+17%
−$36.1M−$40M−$33.6M−33%−$29M−27%−$35.6M−2%−$32.4M−19%−$28.5M−15%−$44.1M+52%−$31M−13%−$17.9M−45%−$25.2M−11%−$25.4M−42%
Interest expense$12.8M$12.9M$12.5M+21%$12.7M+23%$13.1M+2%$11.9M−8%$12.2M−2%$13M+3%$13.4M+2%$13M+9%$12.3M+1%$13.5M+4%
Pre-tax income−$45.4M−$39.9M−$45.8M−20%−$35.7M−32%−$43.6M−4%−$31M−22%−$38.4M−16%−$55.4M+55%−$41M−6%−$6.8M−78%−$33M−14%−$16.6M−70%
−$85K$43.2M$163K−69%$234K$90K−$321K$165K+1%$1.3M+436%$0−$404K+26%$0$0
Net income−$46.7M−$85M−$46.6M−22%−$36.5M−25%−$44M−6%−$30.7M−64%−$38.6M−17%−$56.6M+55%−$41M−7%−$6.4M−79%−$33M−15%−$16.6M−71%
−$0.57−$1.03−$0.56−23%−$0.38−37%−$0.42−26%−$0.29−72%−$0.36−36%−$0.50+32%−$0.30−29%−$0.04−86%−$0.21−42%−$0.11−78%
82.3M82.3M82.6M+2%95.7M+18%104.8M+27%105.4M+28%107.2M+30%113.7M+19%136.4M+30%150.3M+43%154.1M+44%155M+36%

Gross profit: 13 periods, Q1 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest ADC Therapeutics SA's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ADCTADC Therapeutics SA$196.6Mn/mn/a2.5×+3%n/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
Peer median$508.6M11.4×13.5×1.4×+7%13.6%

More on ADC Therapeutics SA

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .